Résumé
The analysis of the outcome of 131 patients with limited small cell lung cancer (SCLC) from two consecutive phase II trials which used the same drugs suggested that the intensity of the first course of chemotherapy was a prognostic factor in SCLC. The T3 stage of the TNM classification was the only clinical factor found to be prognostic for overall survival. Irrespective if the T3 stage was controlled or not by multivariate analysis, we found that overall survival rate increased with the dose of cyclophosphamide administered during the first course. A U-shaped dose-response relationship was observed for cisplatinum; survival was ostensibly better for doses ranging from 85 to 105 mg/m2. When both drugs were taken into account in the analysis, the effect on overall survival remained significant.
langue originale | Anglais |
---|---|
Pages (de - à) | 301-308 |
Nombre de pages | 8 |
journal | Lung Cancer |
Volume | 8 |
Numéro de publication | 5-6 |
Les DOIs | |
état | Publié - 1 janv. 1993 |